Advanced Infusion Care (AIC) now offers Eisai infusion therapy LEQEMBI™ (Lecanemab-irmb) humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

Advanced Infusion Care, a division of AIS Healthcare, now offers LEQEMBI™, developed by Eisai Co., Ltd., for the treatment of patients with Alzheimer’s disease.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, May 23, 2023
Information
Tags: 
General Health, Health, Pharmaceutical, Nursing, Managed Care, Insurance, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Accreditation Commission for Health Care, Patient, Physician, AIC, ACHC, URAC, Alzheimer's disease, Disease, Medical device, Pharmaceutical industry, Eisai
Geotags: 
UNITED STATES, NORTH AMERICA, TEXAS, MISSISSIPPI, GEORGIA, VALDOSTA, ALABAMA, FLORIDA
Organisation: 
AIS HEALTHCARE
Summary
Key Points: 
  • Advanced Infusion Care, a division of AIS Healthcare, now offers LEQEMBI™, developed by Eisai Co., Ltd., for the treatment of patients with Alzheimer’s disease.
  • The nationally accredited home infusion teams at AIC collaborate closely with physicians to provide specialized infusion services to patients in their home or at an infusion suite setting.
  • “We’re proud to be able to add LEQEMBI to our growing list of infusion therapies,” said Jud Hall, President at AIC.
  • “This therapy from Eisai can help us provide a new treatment option for patients with Alzheimer’s disease.”
    LEQEMBI is indicated for the treatment of Alzheimer's disease.


Advanced Infusion Care, a division of AIS Healthcare, now offers LEQEMBI™, developed by Eisai Co., Ltd., for the treatment of patients with Alzheimer’s disease.

The nationally accredited home infusion teams at AIC collaborate closely with physicians to provide specialized infusion services to patients in their home or at an infusion suite setting. This new therapy option expands AIC’s ability to better serve Alzheimer’s patients.

“We’re proud to be able to add LEQEMBI to our growing list of infusion therapies,” said Jud Hall, President at AIC. “This therapy from Eisai can help us provide a new treatment option for patients with Alzheimer’s disease.”

LEQEMBI is indicated for the treatment of Alzheimer's disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied. This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with LEQEMBI. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial.

Approved at 100 mg/mL injection for intravenous use by the U.S Food and Drug Administration on January 6, 2023, the therapy is now available at all AIC locations (Valdosta, Georgia; Birmingham, Alabama; Clinton, Mississippi; Panama City, Florida; Dallas, Texas).

Like all AIC patients, those with Alzheimer’s disease will receive a high level of care from AIC, including 24/7 access to clinical and support staff. Every patient is assigned a dedicated team of professionals, including clinical pharmacists, infusion nurse specialists, and intake managers to provide support throughout the treatment process.

For physicians, AIC is a full-service care delivery partner. We also work directly with patients, insurance companies, and physician offices to secure all needed authorizations and complete paperwork.

AIS Healthcare is dually accredited by URAC and the Accreditation Commission for Health Care (ACHC), further setting it apart from other infusion services providers.

Physicians interested in AIC care services should contact their AIC representatives to get started or visit us at www.aiscaregroup.com/our-divisions/infusion-care/

About AIS Healthcare

Advancing quality. Improving lives.

As the leading provider of targeted drug delivery and infusion care solutions, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected in everything we do.

Learn more at aiscaregroup.com.

Copyright: 
Copyright Business Wire 2023